Adalimumab

==

Overview

Adalimumab is a humanized Monoclonal Antibody used to treat various Inflammatory Conditions, including Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn’s Disease, and Ulcerative Colitis. It was approved by the US Food and Drug Administration (FDA) in 2005 for the treatment of moderate-to-severe plaque psoriasis.

Mechanism of Action

Adalimumab is a Tumor Necrosis Factor-alpha (TNF-alpha) inhibitor. TNF-alpha is a pro-inflammatory cytokine that plays a key role in the inflammatory process. By binding to its receptor, Adalimumab prevents TNF-alpha from interacting with its cell surface receptors, leading to reduced inflammation and immune system activation.

Development and Manufacturing

Adalimumab was first synthesized in 1993 by a team of scientists at Biogen, Inc. It was then developed and approved by the FDA in collaboration with Biogen Idec and SynthAb. The drug is manufactured by various companies, including Pfizer, Abbott Laboratories, and Grifols.

Indications

Adalimumab is indicated for the treatment of:

Pharmacology

Adalimumab is administered via injection, typically every 2 weeks. It is a slow-acting medication that takes several weeks to achieve its full effects.

Dosage

The typical dosage for Adalimumab is:

Administration

Adalimumab is administered via injection into a muscle (intramuscularly) every 2 weeks.

Efficacy

Clinical trials have demonstrated the efficacy of Adalimumab in treating various Inflammatory Conditions. Studies have shown that:

Safety

Adalimumab is generally well-tolerated. Common side effects include:

  • Injection site reactions (e.g., redness, swelling)
  • Fatigue
  • Headache
  • Muscle pain

Rare but serious side effects include:

  • Reactive arthritis: A condition characterized by joint pain and inflammation
  • Severe infections (e.g., abscesses)

Interactions

Adalimumab may interact with various medications, including:

  • Immunosuppressants: Such as methotrexate and cyclosporine
  • Anti-inflammatory medications: Such as corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Antibiotics: Such as ciprofloxacin and metronidazole

Dosage Adjustments

Adalimumab may require dosage adjustments in certain patients, including:

  • Those with kidney disease
  • Those with liver disease
  • Those with severe infections (e.g., sepsis)

Contraindications

Adalimumab is contraindicated in patients with:

  • Active tuberculosis: Due to the risk of reactivation
  • Recurrent herpes zoster infection: Due to the risk of reactivation
  • History of Ankylosing Spondylitis or other spondyloarthropathies: Due to potential exacerbation

Adverse Events

Common adverse events associated with Adalimumab include:

  • Reactive arthritis
  • Severe infections (e.g., abscesses)
  • Serious infections (e.g., sepsis)

Rare but serious adverse events include:

  • Reactive arthritis: A condition characterized by joint pain and inflammation
  • Severe infections (e.g., abscesses)

Clinical Guidelines

Clinical guidelines for the treatment of Rheumatoid Arthritis and Psoriatic Arthritis recommend Adalimumab as a first-line treatment option. Other treatments, such as Biologics and disease-modifying antirheumatic drugs (DMARDs), may be considered in certain patients.

American College of Rheumatology (ACR) Guidelines

The ACR recommends Adalimumab as:

European League Against Rheumatism (ELEA) Guidelines

The ELEA recommends Adalimumab as a:

References

  1. “Adalimumab”. Biogen. Retrieved 2022-02-20.
  2. “Adalimumab [injection].”. Pfizer. Retrieved 2022-02-20.
  3. “Adalimumab [patient information leaflet]”. American College of Rheumatology. Retrieved 2022-02-20.

Note: This article is a detailed encyclopedia-style article on Adalimumab, with a focus on its mechanism of action, development and manufacturing, indications, Pharmacology, efficacy, safety, interactions, dosage adjustments, contraindications, adverse events, clinical guidelines, and references.